^
Association details:
| Biomarker: | BRAF V600E |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | GDC 0879 (BRAF inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Antitumor Efficacy of the Novel RAF Inhibitor GDC-0879 Is Predicted by BRAFV600E Mutational Status and Sustained Extracellular Signal-Regulated Kinase/Mitogen-Activated Protein Kinase Pathway Suppression
Excerpt:
In GDC-0879–treated mice, both cell line– and patient-derived BRAFV600E tumors exhibited stronger and more sustained pharmacodynamic inhibition (>90% for 8 hours) and improved survival compared with mutant KRAS–expressing tumors….BRAFV600E mutation predicts for enhanced sensitivity of melanoma, colon, and lung cancer cell lines to RAF inhibitors in vitro.
DOI:
10.1158/0008-5472.CAN-08-3563
